高级检索
当前位置: 首页 > 详情页

Ligustilide ameliorates cognitive impairment via AMPK/SIRT1 pathway in vascular dementia rat

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Guangzhou Univ Chinese Med, Coll Basic Med, Guangzhou, Peoples R China [2]Guangdong Prov Hosp Chinese Med, Dept Neurol, Guangzhou, Peoples R China [3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Neurol, Guangzhou, Peoples R China [4]Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Peoples R China
出处:
ISSN:

关键词: Ligustilide Vascular dementia AMPK SIRT1 Neuronal degeneration

摘要:
Vascular dementia (VaD) is the second cause of dementia after Alzheimer's disease. Ligustilide (LIG) is one of the main active ingredients of traditional Chinese medicines, such as Angelica. Studies have reported that LIG could protect against VaD. However, the mechanism is still confused. In this study, we employed a bilateral common carotid artery occlusion rat model to study. LIG (20 or 40 mg/kg/day) and Nimodipine (20 mg/kg) were orally administered to the VaD rats for four weeks. Morris water maze test showed that LIG effectively ameliorated learning and memory impairment in VaD rats. LIG obviously reduced neuronal oxidative stress damage and the level of homocysteine in the brain of VaD rats. Western blot results showed that pro-apoptotic protein Bax and cleaved caspase 3 increased and anti-apoptotic protein Bcl-2 decreased in the hippocampi of VaD rats. But after LIG treatment, these changes were reversed. Moreover, Nissl staining result showed that LIG could reduce neuronal degeneration in VaD rats. Furthermore, LIG enhanced the expressions of P-AMPK and Sirtuin1(SIRT1) in VaD rats. In conclusion, these studies indicated that LIG could ameliorate cognitive impairment in VaD rats, which might be related to AMPK/SIRT1 pathway activation.

基金:

基金编号: 82004430 81673717 2021A1515011478 2018A0303130053 2017B030314176

语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类 | 3 区 医学
小类 | 3 区 内分泌学与代谢 3 区 神经科学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 内分泌学与代谢 4 区 神经科学
JCR分区:
出版当年[2020]版:
Q3 NEUROSCIENCES Q3 ENDOCRINOLOGY & METABOLISM
最新[2023]版:
Q2 ENDOCRINOLOGY & METABOLISM Q2 NEUROSCIENCES

影响因子: 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者:
第一作者机构: [1]Guangzhou Univ Chinese Med, Coll Basic Med, Guangzhou, Peoples R China
通讯作者:
通讯机构: [2]Guangdong Prov Hosp Chinese Med, Dept Neurol, Guangzhou, Peoples R China [3]Guangzhou Univ Chinese Med, Affiliated Hosp 2, Dept Neurol, Guangzhou, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号